Navigation Links
New Drug, Other Trends To Double Smoking Cessation and Addiction Treatments

With the advent of a possible new blockbuster drug and greater reimbursement levels for the treatment of nicotine, alcohol, and drug addictions, global sales of smoking cessation and addiction treatments are expected to rise from revenues of little over $1.1 billion in 2005 to more than $2.3 billion in 2010, according to Smoking Cessation and Addiction Treatments: A World Market Analysis, a new study released today from Kalorama Information.

Nicotine is clearly the most abused drug worldwide, with over 1.4 billion incidences, including 50 million users in the U.S. alone. Smoking cessation has continually become a particular focus of global health agencies, and the increasing high awareness of effective smoking cessation products have helped to drive market growth.

The market now dominated by GlaxoSmithKline with its Zyban smoking cessation treatment, and Schering-Plough / Reckitt Benckiser with their Suboxone/Subetex substance abuse treatment, is primed for a dramatic change as Pfizer moves into smoking cessation.

"We believe Pfizer's Chantix will acquire the largest share of the market, overtaking GlaxoSmithKline in smoking cessation, and leading all addiction treatments based on the superior effectiveness of Pfizer's product in clinical studies," notes Melissa Elder, the report's author. "To a more limited extent, new drugs in alcohol and substance abuse treatments will also change those markets."

Smoking Cessation and Addiction Treatments: A World Market Analysis includes world incidence and data for nicotine addiction, drug addiction, and alcohol abuse; current and forecasted revenues through 2010; current and forecasted market share with consideration of new players in the market; reviews of current products and new products in the pipeline; and key trends driving pharmaceutical treatments for smoking cessation and drug/alcohol addiction.


'"/>




Page: 1

Related medicine news :

1. FDA Approves New HIV Drug, Viread
2. FDA Approves New Arthritis Drug, Bextra
3. New Drug, Pleconaril speeds recovery from common cold
4. Herceptin Not A ‘Wonder’ Drug, Says The Lanct
5. NGO Files Pre-Grant Opposition Against Anti-HIV Drug, Combivir
6. Life-Saving Cancer Drug, Herceptin Will be Available Free for Breast Cancer Patients in Wales
7. Diabetes Drug, Exenatide, Good For Blood Sugar Levels and Weight Loss
8. FDA Gives Approval for Skin Cancer Drug, Zolinza
9. Was the Warning of a Severe Reaction To a Drug, Overlooked?
10. Anti-Craving Drug, Naltrexone Helps Women Quit Smoking
11. Teen Marijuana Use Does Not Predict Drug, Alcohol Abuse
Post Your Comments:
(Date:7/8/2008)...Pa., July 8 /PRNewswire/ -- The following statemen...rroway Topaz & Kessler, LLP:, Notice is hereby gi...nited States District Court for the Middle Distric...rities of Healthways Inc. (Nasdaq: HWAY ),("Healt...ough February 26,2008, inclusive (the "Class Peri...
(Date:7/8/2008)...ns Cite Patient Concerns about Delays in Oxygen Or..., July 8 /PRNewswire-USNewswire/ -- The new Medica... equipment has created,concern and chaos for benef..., and home medical equipment providers across the ...n areas on July 1., The bidding program has trigg...
(Date:7/8/2008)...N, July 8, 2008) The American Society of Hematolo...ents of its Alternative Training Pathway Grant. Th...encourage the development and implementation of no...mas Abshire, MD, of Emory University, Donald Mahon...id Sternberg, MD, PhD, of Mount Sinai School of Me...
(Date:7/8/2008)...lure Study Validates Use of Pharos Innovation,s Pr...to Reduce Healthcare Utilization and ...uly 8 /PRNewswire/ -- Pharos Innovations, a pionee...clinical and financial,performance improvement thr...ounced today the results from the Iowa Medicaid Co...
Breaking Medicine News(10 mins):Health News:Shareholder Class Action Filed Against Healthways Inc. By The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Health News:Shareholder Class Action Filed Against Healthways Inc. By The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 2Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 3Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 4Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 5Health News:Iowa Medicaid Demonstration Finds Tel-Assurance(R) Remote Monitoring Platform Improved Health Status and Saved $5 Million 2Health News:Iowa Medicaid Demonstration Finds Tel-Assurance(R) Remote Monitoring Platform Improved Health Status and Saved $5 Million 3
...n to the body after the first few minutes of exerc...ew minutes // of exercise, the amount of oxygen p...e heart carries the oxygen to the blood. Research...ages 55 and 75 who had mild hypertension. Research...
...y should be the treatment of choice for heart atta...o to doesn’t offer angioplasty// services and they...eatment. Research has shown heart attack patients ...ngioplasty to open up the clogged blood vessel tha...
... study researchers say the drug gabapentin (Neuron...ve preventive // measure for people with chronic d...leptic drug. Studies have also shown its success i...ues like diabetic neuropathy, postherpetic neuralg...
...or people with high blood pressure and heart failu...at put them at higher risk for heart attacks and s...bout 9,000 men and women from the Heart Outcomes P... older and suffering from heart-related problems o...
Other Medicine News:
(Date:7/8/2008)...es Using Emisphere,s Eligen(R) ... /- Emisphere,Technologies,...om a clinical,study assessing the oral delivery of...sed a delivery-agent-based approach using Emispher...versity Hospital in Basel, Switzerland,by Christop...
(Date:7/8/2008)...ontrol versus Concerta from 30 minutes to six ho... Only Focalin XR provided onset of effect as early...ggests Focalin XR provides comparable efficacy to ... Symptoms of Attention Deficit/Hyperactivity Disor...ity to focus and learn in an educational ...
(Date:7/7/2008)... ANA598 and ANA773 Acting via Independent... Conference Call Today at 2:00 PM PDT, SA...harmaceuticals,Inc. (Nasdaq: ANDS ) announced to...the Toll-Like Receptor-7 (TLR7) mechanism for the,...ical pharmacology testing,and the results of compl...
(Date:7/7/2008)...vidence supporting accuracy of, its biospectrosc...onal conference., BA...re/ -- Molecular,Biometrics, LLC, a privately-held...ols for applications in personalized medicine to m...ealth and disease, presented data from,four new st...
Breaking Medicine Technology:Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations 2Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations 3Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 2Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 3Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 4Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 5Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 6Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 7Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 8Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 2Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 3Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 4Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 5Embryo Viability Studies Support Utility of Novel, Metabolomic Profiling Technology 2Embryo Viability Studies Support Utility of Novel, Metabolomic Profiling Technology 3Embryo Viability Studies Support Utility of Novel, Metabolomic Profiling Technology 4Using evolution UW team creates a template for many new therapeutic agents 310 1Using evolution UW team creates a template for many new therapeutic agents 310 2Saturated Fat 3A Even a Little Splurge May Be Too Much 823 1Saturated Fat 3A Even a Little Splurge May Be Too Much 823 2Saturated Fat 3A Even a Little Splurge May Be Too Much 823 3Weiner Public News First Media Team at National Press Club 5K 822 1Weiner Public News First Media Team at National Press Club 5K 822 2Group B Strep 3A A Threat to Newborns That Doesnt Have to Be 819 1Group B Strep 3A A Threat to Newborns That Doesnt Have to Be 819 2Group B Strep 3A A Threat to Newborns That Doesnt Have to Be 819 3Group B Strep 3A A Threat to Newborns That Doesnt Have to Be 819 4
...ss medication Xenical,(orlistat 120mg) significant... factors such as blood pressure, glycaemic,control...with type,2 diabetes and hypertension, according t...ess on Obesity (ECO), Budapest,Hungary.(1) , ,Thi...established,for Xenical that demonstrates that not...
...f the brain first,affected by Alzheimers disease (...lzheimers/">http://www.nia.nih.gov/Alzheimers/ ),i...er, a brain,imaging study by researchers at the Na...he National Institutes of Health (NIH), has,found....ower middle,part of the brains outer mantle, may r...
Other Medicine Technology:New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 2New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 3New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 4New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 5New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 6Cortex Area Thinner in Youth with Alzheimers-Related Gene 2Cortex Area Thinner in Youth with Alzheimers-Related Gene 3Cortex Area Thinner in Youth with Alzheimers-Related Gene 4
...toscope System incorporates the latest Olympus des...ments for diagnostic and therapeutic procedures. T...d nurses to assemble the most dynamic instrument f...m incorporates uses stainless steel and Teflon, en...
...tem uses Cooled ThermoTherapy® (transurethral ...cisely targeted microwave energy deep into hyperpl...s for durable clinical outcomes. Dual parameter fe...ctal temperatures for optimal therapeutic intrapro...
Fast, accurate SpO2 measurements always within reach.
Incontinence Pessaries
Medicine Products: